The interleukin-6 promoter polymorphism in Gaucher disease:: a new modifier gene?

被引:13
作者
Altarescu, G
Phillips, M
Foldes, AJ
Elstein, D
Zimran, A
Mates, M
机构
[1] Shaare Zedek Med Ctr, Gaucher Clin, IL-91031 Jerusalem, Israel
[2] Shaare Zedek Med Ctr, Inst Genet, IL-91031 Jerusalem, Israel
[3] Shaare Zedek Med Ctr, Dept Med, IL-91031 Jerusalem, Israel
[4] Hadassah Univ Hosp, Osteoporosis Ctr, IL-91120 Jerusalem, Israel
关键词
D O I
10.1093/qjmed/hcg097
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Individuals with Gaucher disease vary significantly with regard to degree of bone disease, but there are no predictive markers for severity of skeletal involvement. Aim: To determine the frequency of polymorphisms of interleukin-6 (IL-6) among patients with Gaucher disease, and the relationship to bone mineral density (BMD) and other markers of disease severity. Design: Case-control study. Methods: Genotyping for the 174G --> C promoter polymorphism of IL-6 was performed in adult patients with Gaucher disease for whom there was concurrent bone mineral density (BMD) data and in healthy Ashkenazi Jewish controls. Results: The prevalence of allelic variants (58% G/G, 36% G/C, and 6% C/C) was similar in Ashkenazi Jewish adults with Gaucher disease as in Ashkenazi Jewish controls, but significantly different (p < 0.05) from that reported among Caucasians. No statistically significant correlation was found between IL-6 genotypes and BMD or markers of severity of Gaucher disease. Patients with the C/C genotype had relatively mild Gaucher disease. Discussion: The IL-6 polymorphisms appear to be distributed differently in Ashkenazi Jews than among other Caucasians. In Gaucher disease, the C/C genotype may be associated with a milder Gaucher phenotype, and may serve as a mitigating genetic modifier.
引用
收藏
页码:575 / 578
页数:4
相关论文
共 16 条
[1]  
Allen MJ, 1997, QJM-MON J ASSOC PHYS, V90, P19
[2]  
BEUTLER E, 1993, AM J HUM GENET, V52, P85
[3]   Thrombocytosis associated with in enzyme replacement therapy in Gaucher disease [J].
Dweck, A ;
Blickstein, D ;
Elstein, D ;
Zimran, A .
ACTA HAEMATOLOGICA, 2002, 108 (02) :94-96
[4]  
Ferrari SL, 2001, ARTHRITIS RHEUM-US, V44, P196, DOI 10.1002/1529-0131(200101)44:1<196::AID-ANR26>3.0.CO
[5]  
2-5
[6]   Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women [J].
Ferrari, SL ;
Ahn-Luong, L ;
Garnero, P ;
Humphries, SE ;
Greenspan, SL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (01) :255-259
[7]   The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis [J].
Fishman, D ;
Faulds, G ;
Jeffery, R ;
Mohamed-Ali, V ;
Yudkin, JS ;
Humphries, S ;
Woo, P .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (07) :1369-1376
[8]   COEXISTENCE OF GAUCHERS-DISEASE AND MULTIPLE-MYELOMA [J].
GARFINKEL, D ;
SIDI, Y ;
BENBASSAT, M ;
SALOMON, F ;
HAZAZ, B ;
PINKHAS, J .
ARCHIVES OF INTERNAL MEDICINE, 1982, 142 (12) :2229-2230
[9]   Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease [J].
Hollak, CEM ;
Corssmit, EPM ;
Aerts, JMFG ;
Endert, E ;
Sauerwein, HP ;
Romijn, JA ;
vanOers, MHJ .
AMERICAN JOURNAL OF MEDICINE, 1997, 103 (03) :185-191
[10]   Interleukin-6 gene polymorphism is related to bone mineral density during and after puberty in healthy white males:: A cross-sectional and longitudinal study [J].
Lorentzon, M ;
Lorentzon, R ;
Nordström, P .
JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (10) :1944-1949